2020 FDA/EMA approvals for new immunotherapy drug technologies and applications

Document Type : Review Article

Authors

1 Center for Nanotechnology in Drug Delivery, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Department of Pharmaceutical Nanotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

10.30476/tips.2021.91207.1097

Abstract

Immunotherapy is a new approach applied in treatment of infections, autoimmune diseases, or cancer by activating or suppressing the immune system. Pre-clinical and clinical investigations on discovering new products with high efficacy and low side effects are still ongoing. Clinical studies revealed numerous advantages of immunotherapy over chemotherapy, including prolonged progression-free survival and improved overall survival rate. However, immunotherapy may cause occasional severe adverse reactions due to an overactive immune system. This review gives an overview of new immunotherapeutic products approved by FDA/EMA in 2020. Moreover, the technologies used in manufacturing monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and CAR-T cells are explained. In 2020, mAbs approved for the first time in management of migraine, autoimmune CNS disease, and thyroid eye disorder. In addition, new ADC and CAR-T cell therapeutics were authorized by FDA for mAb-targeted treatment of metastatic breast cancer and multiple myeloma, and mantle cell lymphoma, respectively. Despite the complexity and ambiguity of the technological development, ADCs and CAR-T cell therapy have great potential for further clinical applications in cancer therapy.

Keywords


1. Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017 Dec;18(12):e731-e741. doi: 10.1016/S1470-2045(17)30607-1. PMID: 29208439.
2. Shields IV CW, Wang LLW, Evans MA, Mitragotri S. Materials for immunotherapy. Adv Mater. 2020;32(13):1901633.10.1002/adma.201901633
3. Milling L, Zhang Y, Irvine DJ. Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev. 2017;114:79-101. doi:10.1016/j.addr.2017.05.011
4. Bookstaver ML, Tsai SJ, Bromberg JS, Jewell CM. Improving Vaccine and Immunotherapy Design Using Biomaterials. Trends Immunol. 2018 Feb;39(2):135-150. doi: 10.1016/j.it.2017.10.002. Epub 2017 Dec 14. PMID: 29249461; PMCID: PMC5914493.
5. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. PMID: 30622344; PMCID: PMC6410566.
6. Tan S, Li D, Zhu X. Cancer immunotherapy: Pros, cons and beyond. Biomed Pharmacother. 2020 Apr;124:109821. doi: 10.1016/j.biopha.2020.109821. Epub 2020 Jan 18. PMID: 31962285.
7. Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. Front Immunol. 2018 Jan 4;8:1751. doi: 10.3389/fimmu.2017.01751. PMID: 29379493; PMCID: PMC5770808.
8. Manis JP, Feldweg AM. Overview of therapeutic monoclonal antibodies. UpToDate Waltham, MA: UpToDate Inc[a┼żurirano 0805. 2020
9. Liu JK. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113-116. Published 2014 Sep 11. doi:10.1016/j.amsu.2014.09.001
10. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020 Jan 2;27(1):1. doi: 10.1186/s12929-019-0592-z. PMID: 31894001; PMCID: PMC6939334.
11. Tiller T. Single B cell antibody technologies. N Biotechnol. 2011 Sep;28(5):453-7. doi: 10.1016/j.nbt.2011.03.014. Epub 2011 Apr 5. PMID: 21473940; PMCID: PMC7102800.
12. Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014 Nov;13(11):1100-1107. doi: 10.1016/S1474-4422(14)70209-1. Epub 2014 Oct 5. PMID: 25297013.
13. FDA. Drug Trials Snapshots: VYEPTI 2020 [Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vyepti.
14. FDA. VYEPTI label 2020 [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf.
15. FDA. DANYELZA label 2020 [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf.
16. Medscape. New Drug Approved for Neuroblastoma Based on MSKCC Research Nov 26, 2020. [Available from: https://www.medscape.com/viewarticle/941675.
17. Markham A. Naxitamab: First Approval. Drugs. 2021 Feb;81(2):291-296. doi: 10.1007/s40265-021-01467-4. PMID: 33616889.
18. FDA. Drugs Trials Snapshot: Danyelza 2020 [Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drugs-trials-snapshot-danyelza.
19. Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs. 2021 Jan-Dec;13(1):1860476. doi: 10.1080/19420862.2020.1860476. PMID: 33459118; PMCID: PMC7833761.
20. FDA. FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma 2020 [Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma.
21. FDA. Drug Trial Snapshots: MONJUVI 2020 [Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshots-monjuvi.
22. Dhillon S. Isatuximab: First Approval. Drugs. 2020 Jun;80(9):905-912. doi: 10.1007/s40265-020-01311-1. Erratum in: Drugs. 2020 May 23;: PMID: 32347476.
23. FDA. FDA approves isatuximab-irfc for multiple myeloma 2020 [Available from: https://www.fda.gov/drugs/development-approval-process-drugs/fda-approves-isatuximab-irfc-multiple-myeloma.
24. Markham A. Margetuximab: First Approval. Drugs. 2021 Apr;81(5):599-604. doi: 10.1007/s40265-021-01485-2. Epub 2021 Mar 24. PMID: 33761116.
25. FDA. FDA approves margetuximab for metastatic HER2-positive breast cancer 2020 [Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer.
26. FDA. Drug Trials Snapshot: MARGENZA 2021 [Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-margenza.
27. Markham A. Teprotumumab: First Approval. Drugs. 2020 Apr;80(5):509-512. doi: 10.1007/s40265-020-01287-y. PMID: 32157641.
28. FDA. Drug Trial Snapshot: TEPEZZA 2020 [Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-tepezza.
29. Heo YA. Satralizumab: First Approval. Drugs. 2020 Sep;80(14):1477-1482. doi: 10.1007/s40265-020-01380-2. Erratum in: Drugs. 2020 Sep 9;: PMID: 32797372; PMCID: PMC7522096.
30. FDA. FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord 2020 [Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-rare-disease-affecting-optic-nerves-spinal-cord.
31. FDA. Drug Trials Snapshots: ENSPRYNG 2020 [Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-enspryng.
32. Frampton JE. Inebilizumab: First Approval. Drugs. 2020;80(12):1259-1264. doi:10.1007/s40265-020-01370-4
33. Markham A. REGN-EB3: First Approval. Drugs. 2021;81(1):175-178. doi:10.1007/s40265-020-01452-3
34. FDA. FDA Approves First Treatment for Ebola Virus 2020 [Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus#:~:text=Today%2C%20the%20U.S.%20Food%20and,in%20adult%20and%20pediatric%20patients.
35. Lee A. Ansuvimab: First Approval. Drugs. 2021 Apr;81(5):595-598. doi: 10.1007/s40265-021-01483-4. Epub 2021 Mar 22. PMID: 33751449; PMCID: PMC7983082.
36. FDA. Drug Trials Snapshot: EBANGA 2021 [Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-ebanga.
37. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021 Jun;18(6):327-344. doi: 10.1038/s41571-021-00470-8. Epub 2021 Feb 8. PMID: 33558752.
38. Barroso-Sousa R, Tolaney SM. Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond. BioDrugs. 2021 Mar;35(2):159-174. doi: 10.1007/s40259-021-00472-z. Epub 2021 Mar 5. PMID: 33666903; PMCID: PMC7933915.
39. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15-29. doi: 10.1146/annurev-med-050311-201823. Epub 2012 Oct 3. PMID: 23043493.
40. Polakis P. Antibody Drug Conjugates for Cancer Therapy. Pharmacol Rev. 2016 Jan;68(1):3-19. doi: 10.1124/pr.114.009373. PMID: 26589413.
41. Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, et al. Antibody-Drug Conjugates: The New Frontier of Chemotherapy. Int J Mol Sci. 2020 Jul 31;21(15):5510. doi: 10.3390/ijms21155510. PMID: 32752132; PMCID: PMC7432430.
42. Walsh SJ, Bargh JD, Dannheim FM, Hanby AR, Seki H, Counsell AJ, et al. Site-selective modification strategies in antibody–drug conjugates. Chem Soc Rev. 2021;50(2):1305-53.10.1039/D0CS00310G
43. Yu B, Liu D. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomark Res. 2019 Oct 31;7:24. doi: 10.1186/s40364-019-0175-x. PMID: 31695916; PMCID: PMC6824118.
44. Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2020 Oct 16;25(20):4764. doi: 10.3390/molecules25204764. PMID: 33081383; PMCID: PMC7587605.
45. Syed YY. Sacituzumab Govitecan: First Approval. Drugs. 2020;80(10):1019-1025. doi:10.1007/s40265-020-01337-5
46. FDA. FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer 2020 [Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-sacituzumab-govitecan-hziy-metastatic-triple-negative-breast-cancer.
47. FDA. Drug Trial Snapshot: TRODELVY 2020 [Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-trodelvy.
48. Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020:1-7.10.1007/s40265-020-01404-x
49. FDA. Drug Trials Snapshots: BLENREP 2020 [Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-blenrep.
50. de la Torre BG, Albericio F. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2020 Feb 9;25(3):745. doi: 10.3390/molecules25030745. PMID: 32050446; PMCID: PMC7037960.
51. Han D, Xu Z, Zhuang Y, Ye Z, Qian Q. Current Progress in CAR-T Cell Therapy for Hematological Malignancies. J Cancer. 2021;12(2):326-334. Published 2021 Jan 1. doi:10.7150/jca.48976
52. Atrash S, Moyo TK. A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma. Onco Targets Ther. 2021 Mar 26;14:2185-2201. doi: 10.2147/OTT.S242018. PMID: 33814917; PMCID: PMC8009535.
53. Masoumi J, Jafarzadeh A, Abdolalizadeh J, Khan H, Philippe J, Mirzaei H, et al. Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects. Acta Pharmaceutica Sinica B. 2020.10.1016/j.apsb.2020.12.015
54. Ma S, Li X, Wang X, et al. Current Progress in CAR-T Cell Therapy for Solid Tumors. Int J Biol Sci. 2019;15(12):2548-2560. Published 2019 Sep 7. doi:10.7150/ijbs.34213
55. Yu S, Li A, Liu Q, Li T, Yuan X, Han X, Wu K. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017 Mar 29;10(1):78. doi: 10.1186/s13045-017-0444-9. PMID: 28356156; PMCID: PMC5372296.
56. EMA. CHMP assessment report 2020 [Available from: https://www.ema.europa.eu/en/documents/assessment-report/tecartus-epar-public-assessment-report_en.pdf.
57. agency Em. Tecartus 2021 [Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus.
58. Price G. Summary Basis for Regulatory Action 2020 [Available from: https://www.fda.gov/media/141093/download.